for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE

Latest Trade

53.76USD

Change

-0.36(-0.66%)

Volume

12,928,756

Today's Range

53.49

 - 

54.49

52 Week Range

33.36

 - 

61.71

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
54.11
Open
53.65
Volume
12,928,756
3M AVG Volume
897.00
Today's High
54.49
Today's Low
53.49
52 Week High
61.71
52 Week Low
33.36
Shares Out (MIL)
5,612.87
Market Cap (MIL)
308,427.00
Forward P/E
12.99
Dividend (Yield %)
2.91

Next Event

Dividend For PFE.N - 0.4000 USD

Latest Developments

More

Pfizer files for Swiss authorization of COVID-19 drug

Canada Receives 30,400 Courses Of Pfizer's COVID-19 Oral Antiviral Treatment; 120,000 More Expected By End-March - Statement

U.S. FDA Approves Pfizer’s Cibinqo For Adults With Moderate-To-Severe Atopic Dermatitis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. Its medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. In the United States, it sells its vaccines products to the federal government, centers for disease control and prevention (CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery networks.

Industry

Biotechnology & Drugs

Contact Info

235 E 42ND ST

NEW YORK, NY

10017-5703

United States

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Albert Bourla

Chairman of the Board, Chief Executive Officer

Angela Hwang

Group President, Pfizer Biopharmaceuticals Group

Payal Sahni

Chief Human Resource Officer, Executive Vice President

Lidia Fonseca

Executive Vice President, Chief Technology Officer and Digital Officer

Rady A. Johnson

Executive Vice President, Chief Compliance, Quality and Risk Officer

Key Stats

2.32 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

53.6K

2019

51.8K

2020

41.9K

2021(E)

82.0K
EPS (USD)

2018

3.000

2019

2.950

2020

2.220

2021(E)

4.232
Price To Earnings (TTM)
16.55
Price To Sales (TTM)
4.45
Price To Book (MRQ)
4.07
Price To Cash Flow (TTM)
12.89
Total Debt To Equity (MRQ)
52.69
LT Debt To Equity (MRQ)
47.89
Return on Investment (TTM)
13.46
Return on Equity (TTM)
10.59

Latest News

Latest News

Canada approves Pfizer's oral COVID-19 antiviral treatment, deliveries delayed

Canada on Monday approved Pfizer Inc's oral antiviral treatment for mild to moderate cases of COVID-19 in adults, but said global supply shortages meant only a few doses would be ready now.

BRIEF-Canada Receives 30,400 Courses Of Pfizer's COVID-19 Oral Antiviral Treatment; 120,000 More Expected By End-March - Statement

* CANADA HAS RECEIVED SHIPMENT OF 30,400 TREATMENT COURSES OF PFIZER’S COVID-19 ORAL ANTIVIRAL TREATMENT; 120,000 MORE EXPECTED BY END OF MARCH - STATEMENT Source text : https://bit.ly/3FGHF2F

Israeli study shows 4th shot of COVID-19 vaccine less effective on Omicron

A fourth shot of COVID-19 vaccine boosts antibodies to even higher levels than the third jab but it is not enough to prevent Omicron infections, according to a preliminary study in Israel.

Macron touts rosy French economy, new jobs ahead of election

President Emmanuel Macron on Monday touted 21 new foreign investment projects in France and a booming economy as proof his economic reforms have been bearing fruit less than three months before a presidential election in which he is expected to run.

BRIEF-Canada has approved Pfizer's COVID-19 oral antiviral treatment - government website

* CANADA HAS APPROVED PFIZER'S COVID-19 ORAL ANTIVIRAL TREATMENT - GOVERNMENT WEBSITE Source text for Eikon: Further company coverage: (Reporting by David Ljunggren)

Canada has approved Pfizer's COVID-19 oral antiviral treatment - CBC

Canada has approved Pfizer Inc's COVID-19 oral antiviral treatment, the Canadian Broadcasting Corp said on Monday, citing sources, and said an announcement could be made later in the day.

Pfizer to boost COVID-19 pill production with French deal

Pfizer will add a production facility for its antiviral COVID-19 pill in France as part of a plan to invest 520 million euros ($594 million) in the country over the next five years, the U.S. drugmaker said on Monday.

BRIEF-GSK And Pfizer Hold Out For 60 Bln Stg Bid For Consumer Health Unit - FT

* GSK AND PFIZER HOLD OUT FOR £60BN BID FOR CONSUMER HEALTH UNIT - FT

U.S. FDA approves drugs from AbbVie, Pfizer to treat eczema

The U.S. Food and Drug Administration approved drugs from AbbVie Inc and Pfizer Inc for treating eczema, a skin disease, the companies said on Friday.

U.S. FDA approves Pfizer's drug to treat eczema

The U.S. Food and Drug Administration approved Pfizer Inc's drug Cibinqo to treat eczema, a skin disease, the company said on Friday.

Mexico approves emergency use of Pfizer's COVID-19 pills

Mexican health regulator COFEPRIS said on Friday it had approved U.S. pharmaceutical company Pfizer's antiviral oral treatment against COVID-19 for emergency use in adults with light or moderate risk of complications.

WHO recommendation on Merck's oral pill likely in early February

The World Health Organization (WHO) is currently reviewing Merck's COVID-19 antiviral oral pill molnupiravir and a recommendation will likely be made by early February, an agency official said on Friday.

Pfizer says it applied for Japan gov't approval for oral COVID-19 drug

U.S. drugmaker Pfizer Inc said on Friday it has applied for Japanese government approval for its oral COVID-19 treatment.

Pfizer says it applied for Japanese govt approval for oral COVID-19 drug

Pfizer Inc said on Friday it applied for Japanese government approval for its oral COVID-19 treatment.

Fact Check-Pfizer CEO's comments on limited COVID-19 vaccine protection refer to the Omicron variant

Recent comments from Pfizer Chief Executive Officer Albert Bourla on how two doses of the Pfizer-BioNTech COVID-19 vaccine offer “very limited protection” against the Omicron variant of the coronavirus have been misrepresented online.

Africa joins race to acquire Pfizer's COVID-19 Paxlovid pills

Africa's top public health body said it was in talks with Pfizer about securing supplies of its antiviral COVID-19 pills for the continent, the latest to join the race for a drug seen as a potential game changer in fighting the virus.

Africa CDC talking to Pfizer about importing its COVID treatment pill

Africa's top public health body is in talks with Pfizer about bringing its treatment pill for COVID-19 to the continent, its director said on Thursday.

South Korea to deploy Pfizer COVID-19 pills as Omicron wave looms

South Korea will begin treating coronavirus patients with Pfizer's antiviral pills on Friday, the first Asian country to do so, as concern mounts over the spread of the highly contagious Omicron variant.

South Korea to deploy Pfizer COVID-19 pills as Omicron wave looms

South Korea will begin treating coronavirus patients with Pfizer's antiviral pills on Friday, health officials said, as concern mounts over the spread of the highly contagious Omicron variant.

Pfizer study shows COVID-19 booster can be given along with pneumonia shot

Pfizer Inc said on Wednesday booster doses of its COVID-19 vaccine can be administered along with its pneumonia vaccine and produced strong safety and immune responses in people aged 65 and above in a late-stage study.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up